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OPEN SOURCEAPPROACHESIN BIOTECHNOLOGY:
UTOPIAREVISITED
Yann Joly·

I.

INTRODUCTION

Tracing its ongm to Greek antiquity,1 intellectual property has become an
institution in modern legal systems worldwide.2 This growing importance of
intellectual property was confirmed with the 1994 adoption of the Trade-Related
Aspects of Intellectual Property Rights Agreement by the World Trade Organization
(WTO), which harmonized the rules of intellectual property amongst the various
members of the international community on the model of developed countries. 3
However enshrined in the legal tradition, intellectual property law has also had its
share of detractors and has recently come under severe criticism.4 The exercise of
intellectual property rights in such diverse fields of creation as music, information
technology, and biotechnology has met with intense opposition from a growing number
of detractors. 5 In the field ofbiotechnology, the critique has become important enough
to arouse the attention of a number of legislative bodies and propel the creation of an
important corpus of normative documents (recommendations, position statements,
declarations, etc.). 6 Surprisingly, this legislative outburst, aimed at correcting certain
deficiencies of the patent system, was driven by a number of theoretical hypotheses
that were unconfirmed by the available evidence. 7 Various solutions have been
proposed in these normative documents to palliate certain presumed failings of the
patent system: compulsory licenses, adoption of moratoria on gene patents, parallel

* Project Manager, Research Associate, Genetics and Society Project, Centre de recherche en droit
public, Universite de Montreal, Montreal, Quebec, Canada; Centre for Intellectual Property Policy, McGill
Faculty of Law, Montreal, Quebec, Canada. The author would like to thank Flora Wahnon (Universite de
Montreal, Centre de recherche en droit public) for her assistance with the manuscript and Leonard Agneta
(University ofMaine School of Law) and Bartha M. Knoppers (Universite de Montreal, Centre de recherche
en droit public) for their insightful comments following the presentation of this material at the Closing in
on Open Science Symposium at the University of Maine School of Law. The author acknowledges the
financial support of the Sciences and Humanities Research Council of Canada and of Genome Quebec.
1. See Pamela 0. Long, Invention, Authorship, "Intellectual Property," and the Origin of Patents:
Notes Toward a Conceptual History, 32 TECH. & CULTURE846, 846 (1991).
2. Ann Hironaka, Changing Meanings, Changing Institutions: An Institutional Analysis of Patent
Legislation, 72 Soc. INQUIRY 108, 113-14 (2002).
3. World Trade Organization, Agreement on Trade-Related Aspects of Intellectual Property Rights,
1994, WTO.
4. Yann Joly, Winds of Change: In re Fisher and the Evolution oft he American Biotechnology Patent
Law, 25 LAWIN CONTEXT67, 71- 73 (2007).
PROPERTYRIGHTS INTHEGLOBALECONOMY(Institute
5. See, e.g., KEITHE. MASKUS, INTELLECTUAL
for International Economics ed., 2000).
6. E.g., Canadian Bioethics Advisory Committee (CBAC), United States Patent Office (PTO), Office
of Technology Assessment, United Nations Educational, Scientific and Cultural Organization (UNESCO).
7. Timothy Caulfield et al., Evidence and Anecdotes: An Analysis of Human Gene Patenting
Controversies, 24 NAT. BIOTECH. 1091, 1091-92 (2006); see also infra Part II.

HeinOnline -- 59 Me. L. Rev. 386 2007

2007]

OPEN SOURCE APPROACHES

387

imports, and more restrictive evaluation of patent applications. Alongside these policy
solutions, the use of cooperative strategies to facilitate the use of patented inventions
has become a particularly popular alternative in academia.
It has been suggested that cooperative strategies-such as open source, patent
pools, and defensive publication---could correct the inadequacies generated by the
application of the patent system to biotechnological inventions without requiring a
major change in current intellectual property laws. Thus, the main justification
invoked in favor ofthe introduction of open source approaches in biotechnology is that
it would remedy the various failings of the patent system. The numerous articles
discussing these approaches all follow a similar structure. 8 The author usually begins
by discussing the idyllic culture of open science that is said to have prevailed in the
pre-1980 academic biomedical research field, and expresses his or her regret at the
recent commercialization of academia and its adverse effect on fundamental research.
He or she then advances his or her central argument in favor of open source as a
solution to the possible existence of an "anticommons effect" in biomedical research
that could slow down or possibly immobilize the progress of science. After reassuring
readers that the introduction of open source approaches would likely prevent such a
catastrophic scenario, the article ends on a positive note by evasively mentioning some
of the more intrinsic benefits of these approaches.
It is not necessarily prudent for proponents of cooperative strategies to use, as a
central part of their argumentation, a negative discourse that focuses largely on
hypothetical risks unsubstantiated by the available empirical evidence. A better
strategy would be to identify and promote the wealth of intrinsic benefits associated
with these strategies in order to keep them attractive, independent from any evaluation
of the patent system.
This Article will begin with a discussion of the patent system and of the
cooperative approaches to licensing. It will then investigate the claim that the patent
system has created an anticommons effect in the field ofbiotechnology by evaluating
the available empirical data in order to determine whether open source approaches are
needed to improve this situation. This Article will then present the various intrinsic
benefits of the open source approaches reported in current academic literature.
Ultimately, the Article will conclude that the collaborative approaches' intrinsic
advantages not only justify the use of such methods in the biomedical research sector,
but could also allow the sector to become more dynamic and functional.
II. OPEN SOURCE AS AN ALTERNATIVE TO INTELLECTUAL PROPERTY?

A. Intellectual Property: A Contemporary Perspective
A patent is a property right limited in time. It is granted by a patent office upon
the filing ofa patent application to an inventor, giving him the exclusive right to work
his invention in the country (or countries) where the patent was granted. Although
patents constitute a form of intellectual property, they do not confer property rights on

8. E.g., Arti K. Rai, "Open and Collaborative" Research: A New Model for Biomedicine, in
INTELLECTUAL
PROPERTYRIGHTSIN FRONTIERINDUSTRIES,131-58 (Robert W. Hahn ed., 2005); Matthew
Herder, Presentation at Dalhousie Law School: Open Sourcing Stem Cells in Canada (March I 0, 2006).
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the physical manifestation of the intangible invention. 9 The patent owner will need to
conform to the regulatory framework applicable in the country where the invention will
be used. A valid patent must also meet certain legal patentability criteria: utility,
novelty, and non-obviousness. 10 An acceptable patent application will need to describe
the invention precisely and completely, and must contain a description of the best
mode known to the inventor for carrying out the invention. 11 Fees will need to be paid
to the patent office in order to obtain and maintain the patent right on the invention. 12
Patents are also expensive; the minimum cost to obtain and maintain a relatively
simple patent in the United States for twenty years is around $10,000. However,
extending this patent to nine other countries could cost between $160,000 and
$330,000, according to a research from the United States General Accounting Office. 13
It is also costly to enforce patents: legal defenses typically cost $1.6 million per
contested patent. 14 The high price of patents makes them tools that are better suited for
large companies than for independent inventors. Mechanisms used to enforce or
challenge patent rights are perceived by some as unpractical, time consuming, and
expensive. 15 These limitations explain, in part, the large number of bad patents in
existence. 16
The patent system is usually justified on utilitarian grounds as a tool to stimulate
the innovation and development of inventions for the greater good of society. 17 The
inventor benefits from an exclusive right, limited in time, on his invention in exchange
for publicly divulging it. Thus, according to its proponents, the system promotes both
the interests of the inventor-who
is given a means to recuperate the financial
investments made for his invention-and
the interests of the public-which is allowed
to access information that would otherwise be held as a trade secret. 18 However, this
argument also demonstrates the existence of a fundamental contradiction within the
patent system. The system aims to stimulate innovation by granting an exclusive right
to the inventor, who will then have the means to restrict the use and the perfecting of
his invention by others. 19 Aware of this apparent contradiction, economist Joan
Robinson commented, "Since it is rooted in a contradiction, there can be no such thing
as an ideally beneficial patent system, and it is bound to produce negative results in

9. Yann Joly, Biotechnologies et brevets: le cas de la pharmacogenomique, 10 LEX ELECTRONICA
I, 9, Ete 2005, available at http://www.lex-electronica.org/articles/v!0-2/joly.pdf.
10. Patent Act, 35 U.S.C. §§ 100-103 (2000).
11. Joly, supra note 9, at 10.
12. See Patent Act, 35 U.S.C. § 41 (2000).
13. United States General Accounting Offices, Report to Congressional Requesters IO (GA0-02- 789)
(2002).
14. David Malakoff, Will a Smaller Genome Complicate the Patent Chase?, 291 SCIENCEI 194, I 194
(2001).
15. Id. at I I 94; Pamela Samuelson, Legally Speaking: Why Reform the US. Patent System?, 47 COMM.
ACM I 9, I 9 {2004); Brian Kahin, The Expansion of the Patent System: Politics and Political Economy,
6 FIRSTMONDAY,Jan. 8, 200 I, available at http://www.firstmonday.org/issues/issue6 _ 1/kahin/.
16. Mark Lemley et al., What to Do About Bad Patents, 28 REGULATION
10, Winter 2005-06, at 10.
17. William Fisher, Theories of Intellectual Property, in NEW ESSAYSON LEGALAND POLITICAL
THEORYOF PROPERTY168, 169 {Stephen R. Munzer ed., 2001).
18. Edwin C. Hettinger, Justifying Intellectual Property, 18 PHIL.& PUB. AFF. 31, 48 (1989).
19. Id.
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particular instances, impeding progress unnecessarily, even if its general effect is
favourable on balance." 20
Some of the limitations of the patent system have also become apparent in the
recent harmonization process initiated at the international level by the WTO, which has
seen developed countries of the northern hemisphere export their own highly
protectionist regimes to the rest of the world. It was claimed that the harmonization
would improve international technology transfer for the benefit of developing
countries; emerging evidence, however, has yet to demonstrate such positive results. 21
Moreover, vastly publicized debacles involving patents and access to HIV
medicine-such as the Pretoria trial 22 and the United States-Brazil dispute 23-have
made the patent system highly unpopular. 24 According to several authors, alternative
solutions are needed because the prospect of success in importing strong patent
regimes from developed countries to foster innovation and technology transfer in
developing countries seems unlikely at best.25
The extension of the patent system to the field of biotechnology has also raised
significant criticism. Critics have been quick to point out the risks of the liberal gene
patenting policies in force in the United States and often imitated in other countries.
Genetic patents have been criticized on moral grounds as being dehumanizing, 26 an
affront to human dignity, 27 and incompatible with religious beliefs. 28 Merges and
Nelson argued that broad patents on foundational discoveries could limit the use of
these discoveries in subsequent research and consequently reduce the pace and
direction of new innovations. 29 Heller and Eisenberg suggested that genetic research
tool patents could create a "tragedy of the anticommons," which they define as the
underutilization of a scarce resource caused by multiple owners blocking each other
through the proliferation of fragmented and overlapping intellectual property rights. 30
Shapiro theorized that in some "key industries, including ... biotechnology, the patent
system is creating a patent thicket: an overlapping set of patent rights requiring ...

20. JOANROBINSON,
THEACCUMULATION
OFCAPITAL87 (3d ed., 1956).
21. Keith E. Maskus & Jerome H. Reichman, The Globalization of Private Knowledge Goods and the
Privatization of Global Public Goods, in INTERNATIONAL
PUBLIC
GooDS ANDTRANSFER
OFTECHNOLOGY:
UNDERA GLOBALIZED
INTELLECTUAL
PROPERTY
REGIME3, 23 (Keith E. Maskus & Jerome H. Reichman
eds., 2005).
22. Phann. Mfrs. Ass'n v. President of the Republic of South Africa, Case No. 4183/98 (High Ct. of
S. Afr., Transvaal Provincial Division, Feb. 18, 1998).
23. Request for the Establishment of a Panel by the United States, Brazil-Measures Affecting Patent
Protection, WT/DS199/3 (Jan. 9, 2001).
24. GRAHAM
OUTFIELD,INTELLECTUAL
PROPERTY
RIGHTSINTHELIFESCIENCEINDUSTRIES
224-25
(Ashgate Publishing Company 2002).
25. Maskus & Reichman, supra note 21, at 18.
26. See Leon R. Kass, Organsfor Sale? Propriety, Property, and the Price of Progress, 107 PUB.INT.
65, 76-82 (1992).
27. See id.
28. Joint Appeal against Human and Animal Patenting (May 17, 1995) (on file with the National Press
Club).
29. See Robert P. Merges & Richard R. Nelson, On the Complex Economics of Patent Scope, 90
COLUM.L. REV. 839, 845-49, 908-09 (1990).
30. Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? The Anticommons in
Biomedical Research, 280 SCIENCE698, 699-700 (1998).
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those seeking to commercialize new technology [to] obtain licenses from multiple
patentees." 31 Blumenthal concluded that commercial incentives are responsible for
significant delays in the publication of research findings and stifled collaboration,
especially in the field ofbiomedicine. 32 Merz and Cho claimed that patents on genetic
tests not only trigger ethical concerns but also pose significant risks to patients, public
health, and to the practice ofmedicine. 33 Finally, Matthijs proposed that the unique
informational content locked away by patenting gene sequences makes it impossible
for researchers to invent around them, essentially creating a de facto "double"
monopoly. 34 Advocates of the patent system answered these critiques with varying
degrees of success. 35
These claimed shortcomings of the system have not shaken the faith of industry
and governments of industrialized countries in intellectual property as an institution.
It is still perceived as being responsible for high levels of innovation, investment, and
concomitant prosperity.
Intellectual property laws may not have been wholly
responsible for this success, but observers believe they played a significant part. 36
Further empirical evidence would be needed in order for critiques to convince
commercial and governmental actors that the patent system might not always be the
most efficient tool to foster research and development, and that the system could
benefit from substantial reforms. 37 Moreover, it has been suggested that the adoption
of improved licensing practices in the public and private sectors would significantly
reduce the prevalence of the claimed adverse effects of the patent system. 38

31. Carl Shapiro, Navigating the Patent Thicket: Cross Licenses, Patent Pools, and Standard-Setting,
in I INNOVATION
POLICYANDTHEECONOMYI 19, 119 (Adam Jaffe et al. eds., 2000).
32. See David Blumenthal et al., Data Withholding in Genetics and the Other Life Sciences:
Prevalences and Predictors, 81 ACAD. MED. 137, 145 (2006); see also David Blumenthal et al.,
Withholding Research Results in Academic Life Science: Evidence from a National Survey of Faculty, 277
]. AM. MED. Ass'N 1224, 1224 (1997).
33. Mildred K. Cho et al., Effects of Patents and Licenses on the Provision of Clinical Genetic Testing
Services, 5 J. MOLECULARDIAGNOSTICS3, 3 (2003); Jon F. Merz et al., Diagnostic Testing Fails the Test,
415 NATURE577,577 (2002).
34. Gert Matthijs, Gene Patenting and Licensing on and Beyond the BRCA Case, IOEUR. Soc'Y HUM.
GENETICS13, 14 (2004).
35. E.g., F. Scott Kieff, Perusing Property Rights in DNA, in PERSPECTIVE
ON PROPERTIESOF THE
HUMANGENOMEPROJECT125, 125-5 I (F. Scott Kieff ed., 2003); David B. Resnik, The Morality of Human
Gene Patents, 7 KENNEDYINST.ETHICSJ. 43, 51-57 (1997); John P. Walsh et al., View from the Bench:
Patents and Material Transfers, 309 SCIENCE2002 (2005) (hereinafter Walsh et al., View].
36. Sigrid Sterckx, Can Drug Patents be Morally Justified?, 11 SCI. & ENGINEERING
ETHICS81, 82
(2005).
37. E. Richard Gold et al., Needed: Model of Biotechnology Intellectual Property, 20 TRENDS
BIOTECH.327, 327 (2002).
38. See Organization for Economic Co-operation and Development (OECD) Guidelines for the
_3453 7_
Licensing of Genetic Inventions, available at http://www.oecd.org/document/26/0,2340,fr_2649
34317658_1_1_1_1,00.html;seegenerallyCanadian
Biotechnology AdvisoryCommittee(CBAC), Human
Genetic Materials, Intellectual Property and the Health Sector (2006), available at http://cbaccccb.ca/epic/intemet/incbac-cccb.nsf/vwapj/CBAC
_Report_ e. pdf/$FILE/CBAC _Report_ e. pdf.
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B. From Open Science to Open Source
According to some authors, the concept of"scientific progress," which originated
in the 16th and 17th centuries, has always been associated with the ideal of free and
open dissemination of scientific knowledge. 39 In the beginning of the 20th century, the
practice of patenting was perceived as unethical by a large portion of the biomedical
academic community. 40 Early sociologists of science theorized that the research
community was motivated by a number of social norms. These norms "operated as
'prescriptions, proscriptions, preferences and permissions ... legitimated in terms of
institutional values . . . transmitted by precept and example and reinforced by
sanctions.'" 41 Regarding the property ofresearch findings, a norm of"communism"
or "communalism," dictated that these were a product of social collaboration, a
common heritage that "should be dedicated to the scientific community.',4 2 In light of
these communalist values, claiming property rights in inventions or keeping discoveries
secret was discouraged prior to 1980.43
Open science is said to have prevailed both in the fields ofbiotechnology 44 and
information technology in the pre-1980 era. 45 In 1980, Congress-following pressures
from economic and legal circles-decided that traditional research norms, even though
they allowed for the deposit of research results in the public domain, did not
sufficiently encourage the development of commercializable products. Consequently,
it adopted several laws favorable to patents and technology transfer to redress the
situation. 46 The most important of these laws is the Bayh-Dole Act, 47 adopted to
facilitate public access to the research financed by the federal government. This law
had the objective ofencouraging small enterprises, universities, and othernot-for-profit
contractors of the federal government to obtain patents on their inventions. 48 Thus, the
1980s started what many have now come to see as an era of commercialization, 49 in

39. See, e.g., Charles Weiner, Patenting and Academic Research: Historical Case Studies, 12 SCI.,
TECH. & HUMANVALVES50, 50-51 (1987).
40. Id.
41. Janet E. Hope, Open Source Biotechnology (Dec. 23, 2004) (unpublished Ph.D. dissertation, The
Australian National University) at 11 (quoting Merton, Certified Knowledge 40-41, 552-53 (1957)),
available at http://opensource.mit.edu/papers/hope.pdf.
42. Rebecca S. Eisenberg, Proprietary Rights and the Norms of Science in Biotechnology Research
97 YALEL.J. I 77, I 83 (1987).
43. Arti Kaur Rai, Regulating Scientific Research: Intellectual Property Rights and the Norms of
Science, 94 Nw. U. L. REV. 77, 88 (1999).
44. Id.
45. John Willinsky, The Unacknowledged Convergence of Open Source, Open Access, and Open
Science, FIRST MONDAY, Aug. I, 2005, available at http://www.firstmonday.org/issues/issuel0_8/
willinsky/.
46. Rai, supra note 43, at 88.
47. Universities and Small Business Patent Procedures Act, Pub. L. No. 96-517, 94 Stat. 3015 (I 980)
(codified at 35 U.S.C. §§ 200-212 (2000)).
48. Arti K. Rai & Rebecca S. Eisenberg, Bayh-Dole Reform and the Progress of Biomedicine, 66 LAW
ANDCONTEMP.PROBS.289, 290 (2003).
49. See Don Chalmers & Dianne Nicol, Commercialisation of Biotechnology: Public Trust and
Research, 6 INT'L J. BIOTECH. 116 (2004); Benjamin Coriat & Fabienne Orsi, Establishing a New
Intellectual Property Rights Regime in the United States; Origins, Content and Problems, 31 RES. POL'Y
1491 (2002).
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which governments of other developed countries imitated United States's pro-patent
policies with varying degrees of success. so
However, this popular binary picture of an ideal "open science" period as opposed
to a grim era of commercialization is in some respects naive and should be
contextualized. The "norms of science" theory was not intended to demonstrate how
science actually is (or was at the time); on the contrary, Merton argued that these
51
Although the
norms were ideals towards which scientists were rather ambivalent.
biomedical academic community demonstrated some resistance to patenting in the
early part of the 20th century, 52 "no ... specific prescriptive norm against seeking
intellectual property existed in the basic biological science community before 1980,

or thereafter." 53

.Moreover, "[a]s sociologists of science have more recent!y

demonstrated, scientists are not specially unbiased, altruistic or cooperative"; their
interactions occasionally result in "fierce controversy, ruthless competition, personal
animosity, greed and dishonesty." 54 Thus, although early 20th century researchers
were, to a certain extent, more inclined to share scientific findings rather than shroud
them in secrecy, the applicability of the "norms of science" theory in the field of
biology is now refuted by scholars from a variety of fields encompassing sociology,
law, and biological science.
In contrast, the programming community that started to emerge after World War
tended
II-and that would eventually become known as "hackers"-undeniably
55
towards the Mertonian ideal. It is thus no surprise that the first open source project
56
The Free Software
was born in the field of information technology in 1984.
toolbox (GNU) and
software
a
on
based
was
Stallman,
Richard
by
created
Foundation,
a general public license (GPL) that would eventually become the backbone of the free
programming community. The GPL license, also called "copyleft," allowed everyone
to run, copy, modify, and distribute modified versions of the program, but it did not
authorize users to add restrictions of their own. 57

50. Aldo Geuna & Lionel Nesta, University Patenting and its Effects on Academic Research: The
Emerging European Evidence, 35 RES. POL'Y 772, 794-97 (2006).
5 I. Stephen Cole, Merton's Contribution to the Sociology of Science, 34 Soc. STUD.SCI. 829, 839
(2004).
52. Weiner, supra note 39, at 50.
53. Scott F. Kieff, Facilitating Scientific Research: Intellectual Property Rights and The Norms of
Science-A Response to Rai and Eisenberg, 95 NW. U. L. REV. 691,692 (2001).
54. Janet E. Hope, Open Source Biotechnology, (unpublished Ph.D. thesis, The Australian National
University) (December 2004), available at http://rsss.anu.edu.au/-janeth/OpenSourceBiotechnology27
July2005.pdf.
55. See Eric S. Raymond, The Revenge of the Hackers, in OPEN SOURCES:VOICESFROMTHEOPEN
(Chris DiBona et al. eds, 1999), available at http://www.oreilly.com/catalog/open
SOURCEREVOLUTION
sources/book/raymond2.html. A more controversial and insufficiently explored source ofinspiration could
originate from elements of the Marxist political theory. Components of both socialism and Marxism can
be found in the works of the major proponents of the Free Software movement. It remains to be verified
whether these ideological ingredients subsisted within the open source approach.
56. The non-rival and non-exclusive aspect of computer data likely facilitated the development of the
open source approach in the field of information technology.
57. See Bruce Perens, The Open Source Definition, in OPEN SOURCES:VOICESFROM THE OPEN
supra note 55.
SOURCEREVOLUTION,
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In 1997, Bruce Perens drafted the Open Source Definition in order to provide an
alternative to the GNU/GPL that would be acceptable to those who did not share
Richard Stallman 's moral objections to proprietary software licensing. In 1998, Eric
Raymond, Bruce Perens, and several others established the Open Source Initiative
(OSI), a non-profit advocacy organization that would act as a certification body for
open source licenses. A certification from the OSI would indicate compliance with the
official Open Source Definition. 58
The use of open source in the field of biotechnology is a recent phenomenon. In
the last decade, biotechnology researchers began borrowing and adapting the
approaches and concepts developed by programmers from the information technology
sector; these efforts to engage in collaborative research were designed to alleviate the
problems that poorer communities were experiencing with respect to accessing
information, reduce the extent of overlapping patents, share the financial risk of highly
exploratory research, and make biotechnology innovation tools widely available. 59
Inspired by Mertonian ideals, an impressive number of open source related initiatives
started to develop, such as the International HapMap Project, the International Stem
Cell Forum, the CAMBIA Biological Innovation for Open Society (BIOS) Initiative,
the Open Source Stem Cell Research Platform, the SNP Consortium, and the P 3G
Observatory. 60
The open source biotechnology movement is still in its infancy and promises to
be much more heterogeneous than its information technology counterpart.
Biotechnology projects associated with open source do not necessarily use methods
similar to that of Richard Stallman or that would meet the Open Source Definition
developed by Bruce Perens. Open source is often used as a catch-all category that
designates a variety of approaches 61 aimed at facilitating the dissemination of
biotechnology research results and fostering scientific collaboration. For example, the
SARS IP Working Group and the SNP Consortium are both mentioned in the literature
as examples of successful open source initiatives. 62 However, the SARS IP Working

58. Id.
59. Robin C. Feldman, The Open Source Biotechnology Movement: Is It Patent Misuse?, 6 MINN.J.L.
SCI.& TECH.117, 135 (2004).
60. International HapMap Project, About the HapMap, http://www.hapmap.org/thehapmap.html.en;
International Stem Cell Forum, About the JSCF, http://www.stemcellforum.org.uk/about_the_iscf.cfm;
for Open Society,
CAMBIA, The CAMBIA BIOS Initiative: Biological Innovation
http://www.cambia.org.au/daisy/bios/1 0/version/live/part/4/data; U.S. Bio Defense Inc., U.S. BioDefense
Stem Cell News, http://www.usbiodefense.com/; Wellcome Trust, The SNP Consortium and International
P3G Project, P3G: Public
HapMap Project, http://www.wellcome.ac.uk/doc%5Fwtd003500.html;
Population Project in Genomics, http://www.p3gconsortium.org/.
61. Some of these approaches include defensive publications, open source innovation clearinghouses,
open source licensing (non-proprietary contractual agreements), open access databases, and open source
patent licenses. Some sources also include patent pools, patent clearinghouses and research exception in
their definition of open source. David Castle, Open Source and Patent Pooling in Canadian Science and
Biotechnology, (forthcoming) (presented at the CBAC conference 2005). However, there are important
technical and/or ideological differences between these collaborative approaches and open source that would
need to be further investigated before such rapprochement can be made.
62. Stephen M. Maurer et al., Finding Cures/or Tropical Diseases: Is Open Source an Answer?, 1
PLoS MEDICINE 183, I 84 (2004), available at http://medicine.plosjoumals.org/archive/15491676/l/3/pdf/10.1371_joumal.pmed.0010056-L.pdf.
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Group is really a patent pool, whereas the SNP Consortium is an example of a
"defensive publication" strategy.
As Janet Hope notes, "[Biotechnology] innovations are far more diverse in ...
composition than software, which is essentially non-physical and instantly
reproducible." 63 Open source biotechnology initiatives have been proposed in the
areas of bioinformatics software, genomic databases, and "wet lab" biology. 64
Bioinformatics could be the most naturally suited of these three areas for the open
source approaches because of its great similarities with computing. 65 The increased
use of collaborative databases on the "open access" model could help to ensure the
availability of fundamental research data or research tools, but might be difficult to
justify from a commercial standpoint with respect to its inability to protect downstream
innovations. Variants of open source, such as the "defensive publication" technique,
could also be used by industry in emerging fields ofresearch (e.g., pharmacogenomics)
where success or future profitability of projects remains highly uncertain. 66 "Wet lab"
system biology projects are less likely prospects for open source. 67 However, even in
the ''wet lab," open source projects could be justified when intractable problems would
otherwise impede the development of breakthrough drugs. 68
III.

THE ANTICOMMONS

DILEMMA IN BIOTECHNOLOGY

Of the numerous critiques of the patent system's application to the field of
biotechnology, the most influential and damaging to date has been the anticommons
theory developed by Michael Heller, and adapted to the field of biotechnology by
Heller and Rebecca Eisenberg. 69 These scholars persuaded a large audience of
academics and policymakers-both at the international and national level-that an
anti commons effect was jeopardizing biomedical research. 70 Many authors supportive
of open source applied variants of the "anticommons theory" to justify its necessity. 71
Since a presumed anticommons effect is the most popular basis used to advocate the
use of an open source model in the field of biotechnology, a careful review of the

63. Janet E. Hope, A New Way to Manage Scientific Intellectual Property, GENEWATCHMAGAZINE,
Jan.-Feb. 2005, available at http://www.gene-watch.org/genewatch/articles/l
8-1 Hope.html.
64. Arti K. Rai, Open and Collaborative Research: A New Mode/for Biomedicine, in INTELLECTUAL
PROPERTYRIGHTSIN FRONTIERINDUSTRIES131, 140-45 (Robert W. Hahn ed., 2005).
65. See id. at 145-47.
66. Rebecca S. Eisenberg, Will Pharmacogenomics Alter the Role of Patents in Drug Development?,
3 PHARMACOGENOMICS
571, 571-73 (2002).
67. Hope, supra note 63.
68. Rai, supra note 64, at 143.
69. See generally Heller & Eisenberg, supra note 30.
70. Id.
71. See, e.g., Sara Boettinger & Dan L. Burk, Open Source Patenting, I J. INT'L. BIOTECH.L. 221
(2004); Hope, supra note 41; Robert P. Merges, Colloquium: A New Dynamism in the Public Domain, 71
U. CHI. L. REV. 183 (2004); Michael S. Mireles, An Examination of Patents, Licensing, Research Tools,
and the Tragedy of the Anticommons in Biotechnology Innovation, 38 U. MICH.J.L. REFORM14 I (2004);
Dianne Nicol & Janet Hope, Cooperative Strategies for Facilitating Use of Patented Inventions in
Biotechnology, 24 LAWINCONTEXT85 (2006); Iain M. Cockburn, Blurred Boundaries: Tensions Between
Open Scientific Resources and Commercial Exploitation a/Knowledge in Biomedical Research (Apr. 30,
2005) (unpublished article prepared for the Advancing Knowledge and Knowledge Economy Conference),
available at http://people.bu.edu/cockburn/cockbum-blurred-boundaries.pdf.
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empirical evidence relating to the effect of patents on biomedical research is necessary
to assess the strength of this argument.

A. The Anticommons Theory
The anti commons theory states that important patented upstream technologies will
be underused (and therefore underdeveloped) due to the concurrent patent rights on
them: a potential downstream inventor could be deterred from engaging in further
research because in order to develop a single downstream product, he would be
required to go through a complex and potentially expensive process of negotiating
licenses with multiple upstream patentees. 72
This problem of "bundling" patents is especially relevant for biotechnological
research because this sector advances most efficiently when knowledge is shared. In
other words, although scientific cooperation fosters progress, such cooperation is
prevented as a consequence of patent rights. It is therefore not surprising that this
"bundling" concept appears frequently in discussions regarding the likely impact of
intellectual property rights in biotechnology. 73
Applying this theory to the field of biotechnology, Heller and Eisenberg argued
that the tragedy of the anticommons is a possible threat to the advancement of this
sector. 74 According to these two scholars, an anti commons is more likely to materialize
in biomedical research than in any other area of intellectual property because of the
high costs of bargaining, heterogeneous interests among owners, and cognitive biases
of researchers (the over-valuation of one's assets, such as patents, and the undervaluation of others' assets) that can lead to bargaining failure. 75 They did not actually
take the position that there currently exists an anti commons in biomedical research, but
rather meant their article to be a warning to policy makers and scientific and academic
communities. 76 According to Heller and Eisenberg, the preconditions for the emergence of an anti commons exists in the biomedical research sector. 77 Therefore, sole
reliance on markets and norms to avoid an anticommons tragedy could be an
inappropriate strategy. 78

B. Analysis of the Existing Empirical Evidence
The emerging evidence does not support Heller and Eisenberg's apprehensions.
Rather, it demonstrates the absence of a generalized anti commons effect in biomedical
research. 79 Reviewing the evidence, a recent article expressed the opinion that "[t]he

72. Hope, supra note 41, at 36.
73. Id.
74. Heller & Eisenberg, supra note 30, at 699-700.
75. Id. at 701.
76. Id.
77. Id. at 700.
78. Id.
79. See, e.g., John P. Walsh et al., Effects of Research Tool Patents and Licensing on Biomedical
Innovation, in PATENTSIN THEKNOWLEDGE-BASED
ECONOMY
285 (Wesley M. Cohen & Stephen A.
Merrill eds., 2003) [hereinafter Walsh et al., Effects]; Walsh et al., Views, supra note 35; JOSEPHSTRAUS
ET AL., GENETICINVENTIONS
ANDPATENTLAW:AN EMPIRICAL
SURVEYOF SELECTEDGERMANR & D
lNSTITUTIONS(2004)
(unpublished manuscript, on file at the Max Planck Institute for Intellectual Property,
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empirical research suggests that the fears of widespread anti commons effects that block
the use of upstream discoveries have largely not materialized." 80
This growing body of empirical evidence comes from various small-to-medium
scale surveys representative of both the industry and academia on the effect of patents
and licensing practices on biomedical research and clinical access. An interesting
example is Walsh, Arora, and Cohen's 2003 survey on research tool patenting and
biomedical innovation. 81 The authors conducted seventy interviews with intellectual
property attorneys, business managers, university researchers and technology transfer
officers from six universities, patent lawyers, government and trade association
personnel, as well as scientists from ten pharmaceutical firms and fifteen biotechnology
firms. Although generally positive, the conclusions of their research were somewhat
less idyllic than some recent commentaries have suggested. 82 According to Walsh,
Arora, and Cohen:
Through a combination of luck and appropriate institutional response, we appear to
have avoided situations where a single firm or organization using its patents has
blocked research in one or more broad therapeutic areas. However, the danger
remains that progress. in a broad research area could be significantly impeded by a
patentholder trying to reserve the area exclusively for itsel£83

Focusing on the most negative findings of this study, there still does not seem to
be enough evidence to support the position that there exists a substantial "anti commons
effect." The study does agree with Heller and Eisenberg that the preconditions of an
"anticommons effect" ( characterized by the existence of a large number of patents,
owned by different parties with different agendas) seem to exist. 84 Indeed, the patent
landscape has become even more complex since Heller and Eisenberg's 1998 article.
For example, concerns about licensing costs for research tools were reported by half
of the respondents in Walsh, Arora, and Cohen's 2003 study. 85 Other disturbing facts
include the widespread complaints from universities, biotechnology firms, and
pharmaceutical representatives over patent holders' assertions of exclusivity over an
important class of research tools that include "any cell receptor, enzyme, or other
protein implicated in a disease." 86 Also significant is the fact that all respondents who
addressed the question of negotiation delays noted that dealing with research tool
patents caused significant delays and added to research costs. These respondents felt

Competition and Tax Law); Stephen Hansen et al., The Effects of Patenting in the AAAS Scientific
Community (2006), available at http://sippi.aaas.org/survey/AAAS_IP _Survey_Report.pdf; Sadao
Nagaoka, An Empirical Analysis of Patenting and Licensing Practices of Research Tools from Three
Perspectives, Presentation at the OECD Conference on Research Use of Patented Inventions (May 18-19,
2006), available at http://www.oecd.org/dataoecd/20/54/36816178.pdf;
Dianne Nicol & Jane Nielsen,

Patents and Medical Biotechnology: An Empirical Analysis of Issues Facing the Australian Industry
(Centre for Law & Genetics, Occasional Paper No. 6, 2003), available athttp://www.ipria.org/publications/
workingpapers/ BiotechReportFinal.pdf.
80. Caulfield et al., supra note 7, at 1093.
81. Walsh, et al., Effects, supra note 79, at 335.
82. See, e.g., Caulfield et al., supra note 7, at 1092.
83. Walsh, et al., Effects, supra note 79, at 335.
84. See Heller & Eisenberg, supra note 30 and accompanying text.
85. Walsh, et al., Effects, supra note 79, at 293-94.
86. Id. at 310.
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that the process of sifting through a large number of potentially relevant patents and
subsequent negotiations was extremely time consuming. Walsh, Arora, and Cohen also
recognized an important limitation to their study design: the difficulty of measuring the
extent to which projects were not started or had been redirected because of patent
concems. 87
Despite these hurdles, Walsh, Arora, and Cohen's study concluded that one of the
main reasons that no projects were stopped due to the issue of access to research tools
is that industrial and university researchers had been able to develop ''working
solutions." 88 Examples of these solutions include inventing around, going offshore,
and infringement. However, the conclusion that researchers need to either infringe
patents or go offshore to proceed with their research plans should not necessarily be
interpreted as a positive sign. Ifthere is no problem accessing research tools, then why
must people resort to such drastic working solutions? This being said, the study results
nevertheless demonstrate that there is no systemic anticommons effect in the
biomedical industry.
89
Other studies on the topic offer similar, if not less worrisome, findings.
According to these studies, there are some grounds for concern, but there does not
seem to be a widespread anticommons effect in biomedical research. It is worth noting
90
that several guidelines relating to licensing practices have been issued in recent years.
Once implemented by the industry and technology transfer offices, these guidlines
could further reduce the risk of an anti commons effect. Consistent with the findings
of Walsh, Arora, and Cohen, most contemporary studies report a difficulty in precisely
assessing the number ofresearch projects that were abandoned ( or never initiated) due
to problematic patents in the selected area. In 2005, a larger study from Walsh, Cho,
and Cohen found that academic research "offer[ ed] little empirical basis for claims that
restricted access to intellectual property is currently impeding biomedical research,"
and indicated that, "for the time being, access to patents on knowledge inputs rarely
91
imposes a significant burden on academic biomedical research."
The implications of these empirical findings regarding the existence of an
anticommons or of a widespread patent thicket are important for the future prospects
of open source. According to the findings, although the patent system might be
responsible for a number of minor impediments in biomedical research, claims of a
92
If the central
generalized problem of access to research tools are unsubstantiated.
argument to justify the introduction of open source licensing approaches is a risk that
is both hypothetical and uncorroborated by the available evidence, then this argument
seems both intuitively and empirically flawed. In the last part of this Article, I shift

87. Id. at 303.
88. Walsh, et al., Effects, supra note 79, at 322.
89. See Straus et al., supra note 79; Hansen et al., supra note 79; Nagaoka, supra note 79; Nicol &
Nielsen, supra note 79.
90. See ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT [OECD], Guidelines for
the Licensing of Genetic Inventions (2006).
91. Walsh et al., Views, supra note 35, at 2003.
92. One important exception is in the area of human gene patents that cover diagnostic genetic tests
and therapies. There are several instances of researchers and firms claiming that the patent owner is
asserting exclusivity or license terms that are considered inappropriate. See Cho et al., supra note 33; Merz
et al., supra note 33.
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focus from this "negative approach" to open source licensing to a more "positive
approach," through which open source could be justified on intrinsic merits rather than
unsubstantiated fears.
IV. THE BENEFITS OF USING OPEN SOURCE APPROACHES

The intrinsic benefits of the various cooperative strategies for facilitating the use
of patented inventions in biotechnology have been insufficiently investigated in the
academic literature. They are usually only briefly mentioned with little explanation or
evidence to support them. 93 If collaborative approaches are to be successfully
promoted in biotechnology, it is imperative that these benefits take a more central
position in the dialogue. Thus, the following section will concentrate on the intrinsic
benefits that could be fostered by using open source approaches in this field. These
potential benefits were selected because they apply in general to these types of
approaches rather then to a specific commercial strategy implicating particular actors.
The list is not exhaustive and should only be used as a basis for others to build upon.
Also, given that the private sectors, university technology transfer offices, and not-forprofit organizations often have different objectives, the same benefit will likely weigh
more in the balance for some than it will for others.
The negative, hypothetical argument on the systemic failing of the patent system
in biotechnology could still be considered in the assessment, but it should not be given
additional importance, a more central position, or priority over any of the intrinsic
benefits inventoried below.

A. Scientific Benefits
I. Peer Evaluation and Validation of Findings
The transparent nature of an open source system plays an important role in
eliminating errors. The objective of open approaches is to make knowledge available
to the broader public, which is a major requirement for criticism essential in the
learning process. Similarly, open source licenses would likely diminish the need for
secrecy around patent applications in the private sector.
Culture is not merely a social control mechanism. It can also have a role in the
activation and channeling of criticism and in error correction, and therefore plays a part
in the process of innovation and learning in a distributive system. Open development
exposes new input to all interested eyes and thus encourages an open, critical
discussion in order to foster higher quality research. In the course of such peer review,
the contributor's reputation improves by creating useful solutions and contributing
sound critical evaluations of the work of others. On the one hand, the quality of prior
submissions becomes a currency that developers exchange for the community's
attention to their next submission; on the other, the criticism received allows all parties
to evaluate the quality of the work. 94

93. See, e.g., Merges, supra note 71, at 196; Herder, supra note 8, at 38.
94. See Gwendolyn K. Lee & Robert E. Cole, From a Firm-Based to a Community-Based Model of
Knowledge Creation: The Case of the Linux Kernel Development, 14 ORG. SCI. 633,639 (2003).
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2. Increase Intellectual Curiosity and Motivation
Intellectual curiosity is one of the main incentives for joining an open source
project in the field of information technology. 95 It could also be a contributing factor
when applied to open source biotechnology initiatives. Exposure to new ideas, refining
scientific skills, and being part of a community that is able to recognize personal
achievements are important elements of the rewards that an individual expects when
dedicating his or her time to an open source project. It has been observed that having
the choice and opportunity for self-direction actually enhances enjoyment and
motivation, and also affords a greater sense of autonomy, challenge, and stimulation. 96

3. Maximize Rational Development
As Niman and Kench have noted, open source projects could maximize the
potential value of new developments and ideas:
[R]ather than achieving benefits ex post (after the first innovation has been created)
[open source] expands diffusion ex ante by drawing in as many as possible in the
initial development of the idea .... Each user becomes a potential source of new ideas
for future directions in the product, and the workload for implementing change is
shared between an expanded group of developers. 97

Moreover, the increase in communication and exchange encouraged by open source
will likely allow a more modular and effective coordination ofresearch projects. 98

4. Facilitate Sharing of Technical Information
A collaborator would typically be encouraged to learn as much as possible in order
to make technical contributions instead of asking general questions. Having learned
about the technical details of the project, the collaborator can contribute more actively
and effectively to the ongoing technical discussion. 99

5. Facilitate Technology Transfer and Access to Health in Developing Countries
A recent Canadian study highlighted the potential of biotechnologies for
improving health in developing countries. 100 New solutions to developing treatments

95. Josh Lerner & Jean Tirole, The Economics of Technology Sharing: Open Source and Beyond, 19
J. ECON. PERSP.99, 105 (2005).
96. Yan Li et al., Motivating Open Source Software Developers: Influence of Transformational and
Transactional Leaderships, in SIGMIS CPR '06: PROCEEDINGSOF THE 2006 ACM SIGMIS CPR
CONFERENCEON COMPUTERPERSONNELRESEARCH:FORTY FOUR YEARS OF COMPUTERPERSONNEL
RESEARCH:ACHIEVEMENTS,CHALLENGES& THEFUTURE34, 39-40 (2006), available at http://delivery.
acm.org/10.1145/1130000/1125182
/p34li.pdf?keyl=l 125182&key2=4938971611&coll=GUIDE&dl=
GUIDE&CFID=3075455&CFTOKEN=5
l 623844.
97. Neil B. Niman & Brian T. Kench, Open Source in the Pharmaceutical Industry, PROC. MIDWEST
Bus. ECON. Ass'N 124, 127 (2003), available at https://www.usi.edu/business/rnbea/2003/WordFiles/
NIMAN-KENCH.doc.
98. Hope, supra note 54, at 199.
99. Georg von Krogh et al., Community, Joining, and Specialization in Open Source Software
Innovation: A Case Study, 32 RES. POL'Y 1217, 1229 (2003).
100. See Abdallah S. Daar et al., Top Ten Biotechnologies for Improving Health in Developing
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for rare diseases or for diseases found in poor nations may come from open source
research practices in biotechnology. Such approaches can foster biomedical innovation
while significantly reducing research and development expenditures, which often pose
barriers to new drug development for combating many neglected diseases. 101
Assistance from developed countries could take the form of public databases
containing information on biological data, the development ofnew research tools, and
promising therapeutic molecules. Alternatively, a collaborative open-source drug
discovery project such as the Tropical Disease Initiative proposed by Maurer, Rai, and
Sali could be implemented. 102

B. Economic Benefits
1. Reduce Duplication
The open licensing of scientific results will generate a greater overall transparency
and a reduction in costs. Because peers will be able to learn more quickly and easily
when they are working on open source projects, they will avoid the excess costs
generated by the duplication of their research efforts. 103

2. Develop Market for Complementary Goods and Services
Open source licensing can potentially foster a user base for the technology,
''thereby growing the market for complementary goods and services and perhaps even
establishing a defacto industry standard." 104 It would be advantageous for a company
to use an open source license when it expects to boost its profits from these
complementary goods and services; in other words, when profit in the complementary
segment can offset "profit that would have been made in the primary segment, had it
not been converted to open source." 105 In this situation, the invention made available
through open source can serve as an enticement to attract customers to the proprietary
goods and services of the company. 106

3. Enhance Reputation and Public Relations
Private biotechnology companies can enhance their reputations by using open
source. By making the technology they develop freely available to the general public,
these companies can boost their reputations for innovation and expertise, as well as
user-friendliness and social-mindedness. 107

Countries, 32 NATUREGENETICS229 (2002).
IOI. Luis A. Salicrup & Lenka Fedorkova, Challenges and Opportunities for Enhancing Biotechnology
and Technology Transfer in Developing Countries, 24 BIOTECH.ADVANCES69, 73 (2005).
102. See Maurer et al., supra note 62.
I 03. See Jean-Michel Daile & Paul M. David, The Allocation of Software Development Resources, in
'OPEN SOURCE'PRODUCTION
MODE 88 (The Stanford Institute for Economic Policy Research, SIEPR
Discussion Paper No. 02-27, 2003), available at http://opensource.mit.edu/papers/dalledavid.pdf.
104. Hope, supra note 54, at 152.
105. Lerner & Tirole, supra note 95, at 106.
106. See Hope, supra note 63.
107. Id.
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4. Share Financial Risk in Projects
Because biotechnological research requires significantly more capital investment
than other fields of innovation, it is often the case in this field that the only way to
obtain the desired final product is to share the burden of innovation. ms Additionally,
there are limits to the foresight and control of firms over how certain biotechnology
sectors will unfold and where commercial benefits will fall. By joining efforts via a
"copy left" style license or a public database, each firm minimizes the risk of paying
excessive prices for future licenses on important research tools while retaining the right
to patent downstream innovations developed with the help of these tools. 109
The SNPs Consortium illustrates this beneficial use of open source in the
biotechnology sector. A non-profit foundation organized for the purpose of providing
public genomic information, the SNPs Consortium publishes data that is pivotal for
subsequent downstream pharmacogenomic research via a publicly accessible computer
database. In addition to industry giants such as AstraZeneca, Aventis, Bayer, BristolMyers Squib, Hoffman-La Roche, Pfizer, and SrnithKline Beecham, i rnthe independent
charity fund Wellcome Trust collaborated in this open source project.

5. Attract Volunteer Labor
Open source collaborations in the field ofinformation technology demonstrate that
it is possible to extract a substantial amount of labor from unpaid, highly trained
manpower. 111 Volunteers respond to the "supply side" incentives of idealism, learning
new skills, and impressing potential employers. 112 The use of open source can prevent
the "private appropriation of volunteer labor," thus providing "an incentive for
volunteers to contribute in the first instance." 113 These types ofincentives might work
equally well in the field of biotechnology. 114

6. Eliminate Time-Consuming Negotiations
In a project using an open source style license, potential problems with
"contractual non-uniformity [would be] eliminated because each party desiring ...
access to the confidential protected commons must sign a standard licensing
agreement." 115 Technical and legal language and clauses dealing with issues that are
not central to the transaction generally make a license more difficult to read and understand, though they typically make it easier to enforce. Open source licenses-such as

108. Id.
109. Eisenberg, supra note 66, at 572.
110. Smith Kline Beecham became GlaxoSmithKline after a 2000 merger.
111. Stephen M. Maurer, New Institutions for Doing Science: From Databases to Open Source Biology
13 (Nov. 19, 2003), available at http://www.merit.unimaas.nl/epip/papers/maurer_paper.pdf. (paper
presented to the European Policy for Intellectual Property Conference on Copyright and database protection,
patents and research tools, and other challenges to the intellectual property system),
112. Id.
I 13. Rai, supra note 64, at 137.
114. Maurer, supra note 111, at 13.
115. Joseph Eng, Jr., From Software to Life Sciences: The Spreading of the Open Source Production
to New Technological Areas, 24 TEMP. J. SCI. TECH. & ENVTL.L. 419,438 (2005).
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the GPL used in the information technology sector-do not contain such technical
language, making them popular with their users. 116 Moreover, companies can decide
to give away the data by placing it in the public domain, thus avoiding not only
negotiation ofIP access among themselves and other companies down the line, but also
the considerable costs associated with patent protection. 117

7. Customizable
U nderopen source approaches, changes to the product will not only originate from
a small group of scientists under the leadership of a management team that might not
fully anticipate the needs of the market, but rather from those who are actually using
the product in real world situations. As a result, the whole product can eventually
move in a direction that is more closely aligned with the needs of its users than with
those of its developers. As Niman and Kench have noted, the improvements are
"driven from a bottom up approach where end-users both initiate and implement
modifications based on real needs," making the invention more attractive and useful
to its users. 118

8. Produce Usable Output at a Lower Cost
If highly skilled collaborators use an open source approach to undertake the
fundamental research, sponsors could avoid overpaying the research and development
costs that are so difficult to estimate in the early stages. Moreover, because the
intellectual property would be accessible to everyone, any company could manufacture
the good, and the resulting competition would likely keep down the market price for
the completed product. 119 In the case of drug development incentives, governments
and charities could invite companies to bid against each other for the right to perform
further development under contract. Competitive bidding is a powerful method for
containing costs. 120
C. Social Benefits

1. Increase Respect of Peers
As Lerner and Tirole have illustrated, an open source environment fosters greater
transparency, making it easier for peers to signal the production of a higher level of
work since they can see each contribution made by individuals participating in a given
project. They can also detect ''whether that component 'worked,' whether the task was
hard, if the problem was addressed in a clever way, and whether the [contribution] can
be useful for other tasks in the future." 121 This peer monitoring process, in turn, will
likely spur an increase in efforts by the contributor. In the field of information
technology, it has been demonstrated that developers tend to allocate their efforts

116.
117.
118.
119.
120.
121.

Hope, supra note 54, at 99.
See id. at 91.
Niman & Kench, supra note 97, at 127.
See Hope, supra note 63.
Maurer et al., supra note 62, at 184.
Lerner & Tirole, supra note 95, at 104.

HeinOnline -- 59 Me. L. Rev. 402 2007

2007]

OPEN SOURCE APPROACHES

403

according to the level of recognition and reputation enhancement that the community
attaches to different tasks. 122 Therefore, the greater the significance that peers in this
field attach to a project and the role of the agents, the greater the extent of technical
critique of his or her contribution and the greater the reward that can be anticipated. 123
This proposition could likely apply to the biomedical community as well.

2. Compatible with the Scientific Ethos of Open Science
The use of open source approaches could be the perfect way for academia to
progress toward the "communalism" norm of science embraced by Merton; these
norms recognize that scientific progress does not emerge from a void, but always
depends on the body of knowledge accumulated by previous generations of
researchers. 124 The importance of recognizing this reality is especially marked in the
field ofbiotechnology, in which the technological trajectory is now increasingly reliant
on a broader and less concentrated knowledge base, with various companies
participating in the same technological evolution. 125

3. Improve Coordination
Open source is an efficient way to develop research tools. It facilitates effective
collaboration within the research community-both nationally and internationally-by
enabling the sharing of expertise, resources, and knowledge. Open source projects can
provide a forum to share and generate new knowledge that capitalizes on the efficiency
and power of international collaboration and information exchange. 126 "[F]eedback
from the cumulative results of individual actions" will foster improved coordination
and coherence among the collective of researchers. 127
An example of this type of collaboration is the Public Population Project in
Genomics (P 3 G) Observatory. P 3 G is an international consortium for the promotion
of collaboration and international harmonization between researchers and population
genomic databases. 128 The P 3 G Observatory is a knowledge transfer platform, with a
mission to: ( 1) provide the tools that support researchers in the development,
harmonization and implementation ofresearch projects; (2) disseminate scientific and
technical information developed and collected by P3G Cores and International
Working Groups; and (3) to make the comparison and sharing ofinformation amongst
different studies feasible. 129 Thus, the P 3 G Observatory illustrates that open source can
assist researchers in developing the necessary tools to facilitate the transfer of
knowledge among large genomic database projects, and thereby potentially improve
coordination and coherence in such projects.

122. Daile & David, supra note 103, at 14.
123. Id.
124. Arnold Plant, The Economic Theory Concerning Patents/or Inventions, I ECONOMICA30 (I 934).
125. See Heller & Eisenberg, supra note 30; John P. Walsh, supra note 79.
126. Public Population Project in Genomics, Draft Blueprint 4 (2005), available at
http://www.p3gconsortium.org/docs/blueprint_Draft2005.pdf.
127. Daile & David, supra note 103, at 9.
128. See P3G Project, supra note 60.
129. See id.
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4. Facilitate Access to Information for Leaming and Educational Purposes
The simplest form of open source material is the publication of research. A
number of initiatives exist to link the databases in standardized and non-proprietary
ways that would increase the availability of scientific data. 130 These initiatives allow
students to obtain the latest information relevant to their chosen scientific field while
avoiding the high costs of a standard textbook or other copyrighted material. In
addition, open source biotechnology projects could enable students to benefit from the
latest research tools without them or the university having to worry about possible
infringement suits or the status of the common law research exemption.
Open source could provide students with an opportunity to acquire practical
experience by working on challenging projects while leveraging the cultural values of
collaboration. Unlike contexts outside of academia, working together does not threaten
the income of the academic institution. 131

5. Increase Motivation of Employees
As Lerner and Tiro le have noted, employees are usually motivated by "signalling
incentives," which are characterized by the desire to become well-known through the
improved accessibility of their work. 132 Open source projects permit the individual to
be more visible to the relevant audience-peers, the job market, and venture capital
communities-giving rise to advantages or "strategic complementarities." 133 This, in
turn, propels contributors to work on projects involving a large number of participants
because these efforts result in a higher impact on performance and are more indicative
of talent. 134 It also entails ego gratification through peer recognition because
attribution clauses are often included in open source licenses, allowing others to know
who made which contribution. 135
V. CONCLUSION
The patent system is an intractable feature of contemporary law. Given the
absence of strong empirical evidence, its application to the field of biotechnology is
unlikely to be seriously challenged by purely moral or theoretical arguments. Open
source, while not necessarily incompatible with the patent system, offers a radical
alternative that will foster creativity and a climate of open scientific collaboration.
However, this approach remains controversial in the field of information technology,
where it was originally developed, and it is only present in its nascent stages in the

130. Kenneth Neil Cukier, Community Property Open Source Proponents Plant the Seed ofNew Patent
Landscape, I ACUMEN 54, 58 (2003).
131. Chris Coppola & Ned Neelley, Open Source-Opens Leaming: Why Open Source Makes Sense
for Education 6 (Summer 2004), available at http://www.rsmart.com/assets/OpenSourceOpensLearning
July2004.pdf.
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biotechnology sector. 136 Given the somewhat precarious position of open source, the
arguments raised to promote its introduction in the field of biotechnology need to be
carefully selected. Thus far, the main argument invoked has been a negative one,
based on the existing or potential danger of a biotechnological anticommons effect.
These biotechnology anti commons theorists propose the use of open source approaches
as an ideal solution to a hypothetical problem.
In this Article, I suggested that this kind of argument is both objectively
unsatisfactory and unlikely to convince the major actors of the importance of open
source. I consequently recommended that proponents of open source should instead
focus on the often overlooked intrinsic benefits associated with these approaches. The
final part of this Article enumerated some of the benefits that best justify the use of
open source in biotechnology.
It is unlikely that open source will completely supersede the more traditional
licensing approaches in this dynamic research field. Instead, all of the involved actors
will need to carefully consider the benefits and inconveniences of using such
approaches in each individual circumstance. Sometimes, the use of open source will
complement the patent system; at other times, it will work best as an independent
alternative. A list of intrinsic benefits of open source approaches constitutes an
important tool to assist those making this critical assessment. Open source licensing
presents significant intrinsic benefits that warrant incorporation into the numerous
emerging guidelines on licensing practices.
Due to its unique ideological foundation, open source might eventually come to
confront and threaten the foundation of the patent system. For now, however, it will
need to be promoted to future users on the basis of rational arguments rather than on
negative feelings towards the patent system and hypothetical risks uncorroborated by
currently available evidence.

136. See Thomas B. Kepler et al., Open Source Research-The Power of Us, 59 AUSTL.J. CHEMISTRY
291,294 (2006), available at http://www.publish.csiro.au/?act=view_file&file_id=CH06095.pdf.
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